Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021

JCO Oncology Practice · Published 2026-07-22 · DOI 10.1200/op-26-00120

Authors (8)

Mahnum Shahzad, Rebecca Costa, Stephanie Argetsinger, Dennis Ross-Degnan, Fang Zhang, J. Frank Wharam, Carol L. Rosenberg, Anita K. Wagner

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shahzad, M., Costa, R., Argetsinger, S., et al. (2026). Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021. JCO Oncology Practice. https://doi.org/10.1200/op-26-00120

Related articles

• Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration’s accelerated approval pathway: retrospective observational study and economic evaluation · BMJ Medicine · 2025 · Cites or is cited by this article
• Acupuncture in Cancer Care: Evidence, Safety, and Implementation in Oncology Practice · JCO Oncology Practice · 2026 · Same journal
• Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis · JCO Oncology Practice · 2026 · Same journal
• Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid Tumors · JCO Oncology Practice · 2026 · Same journal
• When Systems Fail the Vulnerable: Cancer Care for Patients With Mental Illness · JCO Oncology Practice · 2026 · Same journal
• Implementing Systems-Based Interventions to Improve the Care of Cancer Survivors: Small Steps, Large Challenges · JCO Oncology Practice · 2026 · Same journal
• Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials · JCO Oncology Practice · 2026 · Same journal
• Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery · JCO Oncology Practice · 2026 · Same journal
• Participation Is Not Reform: Why 340B Discounts Should Follow the Patient · JCO Oncology Practice · 2026 · Same journal
• Dose Optimization and the Implementation of Project Optimus · JCO Oncology Practice · 2026 · Same journal